000273926 001__ 273926
000273926 005__ 20250127091432.0
000273926 0247_ $$2pmid$$apmid:39463030
000273926 0247_ $$2doi$$a10.1111/ene.16520
000273926 0247_ $$2ISSN$$a1351-5101
000273926 0247_ $$2ISSN$$a1468-1331
000273926 0247_ $$2pmc$$apmc:PMC11622321
000273926 037__ $$aDZNE-2024-01400
000273926 082__ $$a610
000273926 1001_ $$00000-0003-0647-5923$$avon der Gablentz, Janina$$b0
000273926 245__ $$aPostural control in episodic ataxia type 2: no evidence for increased vestibular excitability
000273926 260__ $$aOxford [u.a.]$$bWiley-Blackwell$$c2025
000273926 3367_ $$2DRIVER$$aarticle
000273926 3367_ $$2DataCite$$aOutput Types/Journal article
000273926 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1733824096_30057
000273926 3367_ $$2BibTeX$$aARTICLE
000273926 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000273926 3367_ $$00$$2EndNote$$aJournal Article
000273926 520__ $$a Patients with episodic ataxia type 2 (EA2) suffer from recurrent paroxysmal episodes of vertigo and oscillopsia. Pathophysiologically, altered neuronal excitability has been suspected. Vestibular excitability in 22 EA2 patients and 22 age-matched healthy participants was compared.Galvanic vestibular stimulation (GVS) was used to assess vestibular excitability by vestibular motion perception thresholds and mean postural sway velocity during various visual and proprioceptive conditions in the two groups. Control stimuli using sham and no GVS were established to identify the specificity of GVS-induced postural sway.In the baseline condition, EA2 patients showed larger postural instability. However, motion perception thresholds and the increase in mean postural sway velocity during vestibular stimulation (stimulation ratio) did not differ between groups. Postural sway during suprathreshold GVS increased with the vestibular motion perception threshold in EA2 patients, in contrast to healthy participants.The larger postural unsteadiness of EA2 patients probably reflects their progressive cerebellar degeneration. It is not related to abnormal visual (Romberg's ratio) or proprioceptive control of stance. Postural unsteadiness during vestibular stimulation does not indicate altered vestibular excitability in EA2 patients. However, vestibular stimulation increasingly destabilized postural control of EA2 patients with higher motion perception thresholds when proprioceptive information was diminished. This conclusion, however, is restricted to the postural control of EA2 patients in the interval between the vestibulo-cerebellar episodes.
000273926 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000273926 588__ $$aDataset connected to CrossRef, Journals: pub.dzne.de
000273926 650_2 $$2MeSH$$aHumans
000273926 650_2 $$2MeSH$$aFemale
000273926 650_2 $$2MeSH$$aMale
000273926 650_2 $$2MeSH$$aPostural Balance: physiology
000273926 650_2 $$2MeSH$$aMiddle Aged
000273926 650_2 $$2MeSH$$aAdult
000273926 650_2 $$2MeSH$$aAtaxia: physiopathology
000273926 650_2 $$2MeSH$$aVestibule, Labyrinth: physiopathology
000273926 650_2 $$2MeSH$$aVestibule, Labyrinth: physiology
000273926 650_2 $$2MeSH$$aAged
000273926 650_2 $$2MeSH$$aMotion Perception: physiology
000273926 650_2 $$2MeSH$$aElectric Stimulation
000273926 650_2 $$2MeSH$$aNystagmus, Pathologic
000273926 7001_ $$aOverbeeke, Nina$$b1
000273926 7001_ $$aTimmann, Dagmar$$b2
000273926 7001_ $$aGanos, Christos$$b3
000273926 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b4
000273926 7001_ $$aBrüggemann, Norbert$$b5
000273926 7001_ $$00000-0003-2493-2294$$aHelmchen, Christoph$$b6
000273926 7001_ $$00000-0001-9255-7911$$aSprenger, Andreas$$b7
000273926 773__ $$0PERI:(DE-600)2020241-6$$a10.1111/ene.16520$$gVol. 32, no. 1, p. e16520$$n1$$pe16520$$tEuropean journal of neurology$$v32$$x1351-5101$$y2025
000273926 8564_ $$uhttps://pub.dzne.de/record/273926/files/DZNE-2024-01400%20SUP.docx
000273926 8564_ $$uhttps://pub.dzne.de/record/273926/files/DZNE-2024-01400.pdf$$yOpenAccess
000273926 8564_ $$uhttps://pub.dzne.de/record/273926/files/DZNE-2024-01400%20SUP.doc
000273926 8564_ $$uhttps://pub.dzne.de/record/273926/files/DZNE-2024-01400%20SUP.odt
000273926 8564_ $$uhttps://pub.dzne.de/record/273926/files/DZNE-2024-01400%20SUP.pdf
000273926 8564_ $$uhttps://pub.dzne.de/record/273926/files/DZNE-2024-01400.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000273926 909CO $$ooai:pub.dzne.de:273926$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000273926 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000273926 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000273926 9141_ $$y2024
000273926 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J NEUROL : 2022$$d2023-10-22
000273926 915__ $$0LIC:(DE-HGF)CCBYNC4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial CC BY-NC 4.0
000273926 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2023-10-22$$wger
000273926 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000273926 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bEUR J NEUROL : 2022$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-22
000273926 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-22
000273926 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000273926 980__ $$ajournal
000273926 980__ $$aVDB
000273926 980__ $$aUNRESTRICTED
000273926 980__ $$aI:(DE-2719)1210000
000273926 9801_ $$aFullTexts